

AD _____

GRANT NUMBER DAMD17-94-J-4064

TITLE: Interaction of the Tumor Suppressor p53 With Replication Protein A

PRINCIPAL INVESTIGATOR: Anindya Dutta, M.D., Ph.D.

CONTRACTING ORGANIZATION: Brigham & Women's Hospital
Boston, Massachusetts 02115

REPORT DATE: August 1997

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19971230 037

DTIC QUALITY INSPECTED 5

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

| | | | | |
|---|---|--|--|--|
| 1. AGENCY USE ONLY (Leave blank) | | 2. REPORT DATE August 1997 | 3. REPORT TYPE AND DATES COVERED Annual (15 Jul 96 - 14 Jul 97) | |
| 4. TITLE AND SUBTITLE Interaction of the Tumor Suppressor p53 With Replication Protein A | | | 5. FUNDING NUMBERS DAMD17-94-J-4064 | |
| 6. AUTHOR(S) Anindya Dutta, M.D., Ph.D. | | | | |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Brigham and Women's Hospital Boston, Massachusetts 02115 | | | 8. PERFORMING ORGANIZATION REPORT NUMBER | |
| 9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick Frederick, Maryland 21702-5012 | | | 10. SPONSORING/MONITORING AGENCY REPORT NUMBER | |
| 11. SUPPLEMENTARY NOTES | | | | |
| 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited | | | 12b. DISTRIBUTION CODE | |
| 13. ABSTRACT (Maximum 200) <p>Cdc25A, a phosphatase essential for G1-S transition, associates with, dephosphorylates and activates the cell-cycle regulator cyclin-dependent kinase (cdk). p21 is a cdk inhibitor induced by a tumor suppressor such as p53. We identified a cyclin binding motif near the N terminus of Cdc25A that is similar to the cyclin binding Cy motif of p21 family of cdk inhibitors and separate from the catalytic domain. Mutations in this motif disrupt the association of Cdc25A with cdk. A peptide based on the Cy motif of p21 competitively disrupts the association of Cdc25A with cyclin-cdks and inhibits the de-phosphorylation of the kinase. p21 inhibits Cdc25A/cyclin-cdk association and the dephosphorylation of cdk2. Conversely, Cdc25A, which is itself an oncogene up-regulated by the Myc oncogene, associates with cyclin-cdk and protects it from inhibition by p21. These results describe a mechanism by which the Myc- or Cdc25A-induced oncogenic pathways activated frequently in breast cancers are counter-balanced by p53-induced growth-suppressive pathways counterbalance each other by competing for cyclin-cdks.</p> | | | | |
| 14. SUBJECT TERMS p53, DNA Replication, Cell-Cycle, Transformation, Transcription, Breast Cancer | | | 15. NUMBER OF PAGES 23 | |
| | | | 16. PRICE CODE | |
| 17. SECURITY CLASSIFICATION OF REPORT Unclassified | 18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified | 19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified | 20. LIMITATION OF ABSTRACT Unlimited | |

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

A Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.



8/11/97

PI - Signature

Date

TABLE OF CONTENTS:

| | |
|--------------------------|-------|
| Front Cover | 1 |
| Report documentaion Page | 2 |
| Foreword | 3 |
| Table of Contents | 4 |
| Introduction | 5-6 |
| Body | 7-12 |
| Conclusions | 13 |
| References | 14-15 |

This contract is a career development award which supports the salary of the principal investigator. Publications resulting from this work are listed below:

Saha P, Eichbaum Q, Silberman ED, Mayer BJ, Dutta A. (1997) p21/CIP1 and Cdc25A: competition between an inhibitor and an activator of cyclin-dependent kinases. *Mol. Cell. Biol.* 17, 4338-4345.

INTRODUCTION

In the report for 1996, I demonstrated that a change in the direction of research became necessary based on the results published in (1). The results strongly suggested that the main growth suppressive action of p53 derives from its ability to activate transcription rather than binding to and inhibiting RPA. Hence we turned our attention to studying one of the major effectors of p53, a protein variously called p21/WAF1/Cip1. p53 induces the mRNA for this gene, p21 protein product increases and it suppresses cell growth. Indeed, "knock-out" mice with homozygous deletions of the p21 gene lose one of the important effects of p53: despite having wild type alleles of p53 they fail to stop at the G1-S transition following radiation (2, 3). This is an important loss because the G1-S block prevents the cell from replicating its DNA before it has time to repair DNA damage. As a result of this failure to stop at G1-S, DNA damage induced mutations are propagated to the progeny cells. Acquisition of new mutations is now recognized as a hallmark of cancer development and progression. Thus the function of p21 is crucial for normal growth control by p53 and restoring p21 function in p53 mutant cancers could have a therapeutic advantage. Of course, this also means that we need to understand why p21 stops cell growth at the G1-S transition.

In the 1996 report I introduced the cell-cycle and how it is regulated by the periodic appearance of cyclin-cdk activity. The crucial activity at the G1-S transition is the activation of cyclin E-cdk2 and cyclin D-cdk4. During S phase, cyclin A-cdk2 begins appearing. All three activities are essential for the progression of the cell-cycle. p21/Cip1/Waf1 (henceforth referred to as p21), is induced by p53. We showed that the regions of p21 involved in interacting with and inhibiting (i) the cyclin-cdk kinases and (ii) PCNA are separable from each other (4). The N terminal domain of p21 (p21N) interacts with the cdk2 protein and inhibits cyclin-cdk kinase activity, while the C terminal domain (p21C) interacts with and inhibits PCNA. Using these separated domains we showed that p21N inhibits growth of transformed human osteosarcoma cells, SaOs2 suggesting that the minimal requirement for growth suppression by p21 is its ability to inhibit the cyclin-cdk kinases. We also discovered that p21 uses two separate motifs, a cyclin binding Cy motif and a cdk binding K motif which independently bind to the regulatory cyclin subunit and the catalytic cdk subunit (5). Both these motifs and interactions are essential for optimal kinase inhibition and cell growth suppression.

In the addendum to the '96 report I explained how the scientific discoveries necessitated a change in the direction of work, resulting in a revised Statement of Work. The importance of the Cy motif of p21 in interacting with the cyclin-cdk complex was highlighted by our discovery that a 12 amino acid peptide containing this Cy motif could competitively block the association of cyclin-cdk with p21 (5). The X-ray crystal structure of p27 (a member of the p21 family of cdk inhibitors) suggests that the Cy motif of p21 interacts with the MRAIL motif of cyclins and the interaction is independent of a more complicated interaction between the K motif and the catalytic cdk (6). Yet, although both the Cy-cyclin and K-cdk2 interactions are essential for optimal kinase inhibition, the Cy-cyclin interaction appears to be the primary docking interaction which then allows the K-cdk2 interaction to take place. If this docking interaction is blocked then the cyclin-cdk could be partially immunized to the inhibitory action of p21.

We also have evidence from immunocytochemical studies of breast cancers (another project, not supported by the USAMRDC) that up to 10% of the cancers have elevated levels of nuclear p21 but proliferate as though they are resistant to the molecule. No mutations were found in the p21 gene of several hundred tumors (including breast cancers) analyzed (7). Therefore the high frequency of apparent resistance to p21 (10%) cannot be explained by genetic mutations inactivating p21. Based on our observation of the critical role of the Cy motif-Cyclin interaction for kinase inhibition, we hypothesized that a cdk activator (cdk activating kinase CAK or Cdc25) may occupy the MRAIL site on the cyclin and prevent p21 from binding to cyclins and inhibiting the

cdk kinase. Cellular molecules such as these activators could be up-regulated in the breast cancers and impair the action of p21. This would be a novel mechanism by which the cdk inhibitors are bypassed. In addition, a p21 based Cy-mimetic chemical may be even more active in this sub-set of breast cancers because it would prevent the activation of cyclin-cdks by such cdk activators.

Cdc25A: Phosphorylation of conserved threonine and tyrosine residues near the ATP binding sites of Cdks (Thr 14 and Tyr 15 on cdk2) (8) by wee1 and mik1 protein kinases is another important mechanism employed to keep the Cdks inactive. In human cells, there are three known CDC25 genes (CDC25A, CDC25B and CDC25C) (9-11). Cdc25A functions at the G1-S transition during human cell cycle (12-14). Phosphatase activities of Cdc25 proteins are, in turn, regulated by phosphorylation by the cyclin-cdks creating a positive feed-back loop between Cdc25 and the cdk (12, 13, 15, 16). Thus Cdc25A dephosphorylates and activates the kinase activity of Cdk2/cyclin E complex, which, in turn, phosphorylates and stimulates the phosphatase activity of Cdc25A. Recently it was shown that Cdc25A and Cdc25B act as oncogenes (17). They transform primary mouse embryonic fibroblast in cooperation with Ras oncogene and are over-expressed in almost a third of breast cancers. It has also been reported that the oncogene c-Myc directly stimulates Cdc25A expression (18).

BODY

SPECIFIC AIMS FOR YEAR 3 (after revision at the end of year 2)

Year 3 (1996-'97)

Analyze whether cdk activators like cyclins, cdk activating kinase (CAK) and Cdc25 block the association of p21 with cyclin-cdks. Determine *in vitro* whether they antagonize the inhibition of cyclin-cdks by p21. For non-cyclin p21 antagonists determine whether the antagonism of p21 requires that the activator binds to cyclin using a Cy-like motif (Task 4).

METHODS

Protein expression in bacteria and binding reactions: Plasmid pGEX-2T (Pharmacia) containing the human CDC25A cDNAs (9, 11) were used to express the GST fusion proteins in *E. coli* BL21. The site directed mutagenesis was performed as described (1) and the mutant CDC25A was also cloned into pGEX-2T for expressing as GST fusion protein. The affinity purification of the fusion proteins over glutathione agarose were carried out as described before (5). PS100 (ACRRLFGPVDSE) contains the cyclin binding Cy1 motif of p21 and in the control peptide PS101 (ACRRLKKPVDSE) underlined FG are mutated to KK (5). ³⁵S-labeled cyclins were prepared in coupled *in vitro* transcription and translation reaction. The binding reactions were carried out in a total volume of 0.2 ml containing about 1 µg GST fusion proteins on the glutathione agarose beads and ³⁵S-labeled cyclins in buffer A7.4 (20 mM Tris-HCl, pH 7.4 containing 1 mM EDTA, 25 mM NaCl, 1 mM DTT, 10% glycerol, 0.01% NP40) for 1 hour at 4°C on a rotating wheel (4, 5).

Phosphatase assay: cdk2 with Arg-169 mutated to Leu (R169L) is partially active as a kinase and when produced in insect cells has a significant amount of phosphorylation on Tyr-15 (unpublished observations). Cdk2-R169L was expressed along with GST-cyclin E in insect cells and GST-cyclin E/cdk2-R169L was purified. GST-cyclin E/cdk2-R169L (with tyrosine phosphate) was used as substrate in the *in vitro* phosphatase reaction (Fig. 2). Anti-phosphotyrosine monoclonal antibody (anti-PY) and anti-cdk2 polyclonal antibodies were from Upstate Biotechnology Incorporated. The phosphatase reactions were carried out for 15 min. at 30°C in a total volume of 20 µl containing 1 µg GST-cyclin E/cdk2-R169L, 0.5 µg GST-Cdc25A in 50 mM Tris-HCl, pH 8.0, 50 mM NaCl and 2 mM DTT. The reactions were stopped by adding SDS-sample buffer and the products were analyzed by Western blot analysis.

Transfection, immunoprecipitation and pull-down: The wild type and mutant CDC25A cDNAs were cloned into eukaryotic GST fusion protein expression vector pEBG (19) and the transfections into human kidney 293T cells were carried out by Ca₃(PO₄)₂ method (1). The transfected cells were harvested after two days and lysed in 50 mM Tris-HCl, pH 7.4 containing 5 mM EDTA, 0.1% Triton X-100, 1 mM DTT, 250 mM NaCl, 50 mM NaF, 1 mM Na-vanadate, 1mM PMSF, 2 µg/ml aprotinin, 0.5 µg/ml leupeptin, 1µg/ml pepstatin A. A volume of lysate containing 2 mg of total protein was used for immunoprecipitation or pull-down reaction.

Kinase assay: Kinase reaction was carried out at 30°C for 10 min in 50 mM Tris-HCl, pH 7.5 containing 10 mM MgCl₂, 1 mM DTT, 50 µM ATP, 1 µg Histone H1 and 2 µCi [γ -³²P]ATP in a total volume of 20 µl. The reaction was stopped by SDS-PAGE sample buffer and the products were analyzed by SDS-PAGE and autoradiography.

RESULTS

Stable complex formation between cyclins and cdc25 phosphatases

To investigate the interactions between cdc25 phosphatases and cyclins, Cdc25A, B and C proteins were produced as glutathione S-transferase (GST) fusion proteins in *E. coli* and bound to glutathione-agarose beads from the bacterial lysates. Cyclins A, B, D1 and E were prepared as ³⁵S labeled proteins in a coupled *in vitro* transcription and translation reaction using rabbit reticulocyte lysate. Results of the pull-down assays using glutathione beads containing equal amounts of GST-fusion proteins and ³⁵S labeled cyclins are shown in Fig. 1A. None of the cyclins bound to GST. Cyclins E and A bound only to GST-Cdc25A, whereas cyclin B bound to GST-Cdc25A and C. In this assay, cyclin D1 bound to all GST-fused Cdc25 proteins.

Cdc25A contains a putative cyclin binding motif on the N-terminus similar to Cy1 motif of p21^{CIP1}.

p21 has two cyclin binding motifs, Cy1 (amino acid 17-24) and Cy2 (amino acid 152-158) and one Cdk2 binding K site (amino acids 53-58). p27, p57, p107, p130 and E2F1 use a similar motif to interact with cyclin E. The important amino acid residues in the motif are RRLFG. A 12 amino acid long peptide (PS100) derived from the Cy1 region of p21 interrupts the interaction between p21 and cyclin E or cyclin A (5).

Interestingly, human Cdc25A protein contains a similar amino acid sequence at residues 10-14 (RRLFF) and we hypothesized that this sequence is used for the interaction with cyclins. To test this we investigated the effect of PS100 on the association of Cdc25A with cyclins. Fig. 1B shows that when pull-down assays were carried out with GST-Cdc25A and ³⁵S-labeled cyclin E or A in the presence of increasing amount of PS100 peptide, the Cdc25A-cyclin interaction was inhibited. A mutant peptide PS101, where LF residues are changed to KK, did not affect the interaction. Therefore, a Cy1 like motif was important for the interaction of Cdc25A with Cyclins E or A.

If Cdc25A uses a Cy like motif to associate with cyclins, we expect full length p21 protein containing two Cy motifs to also inhibit the interaction of cyclins with Cdc25A. Bacterial lysates containing recombinant p21 was indeed found to inhibit the Cdc25A-cyclin association (Fig. 1C, lanes 3-5).

Effects of p21 and its derivatives on the phosphatase activity of Cdc25A:

Cdc25A removes the inhibitory phosphate groups present on Thr-14 and Tyr-15 of Cdk2. We tested the phosphatase activity of cdc25A on derivatives of cdk2 which are phosphorylated on Tyr-15, the removal of phosphate being followed by immunoblotting with anti-phosphotyrosine (anti-PY) antibody (Fig. 2a, lane 2). Cdk2 levels (as detected by immunoblotting with anti-cdk2 antibody) were unchanged throughout the incubations (data not shown). The Cy motif containing peptide PS100 inhibited the phosphatase activity of cdc25A on cyclin-Cdk2 (lane 3) compared to minimal inhibition by the mutant peptide PS101 (lane 4). A 400 fold lower concentration of p21 (compared to PS100) inhibited the phosphatase activity of Cdc25A on cyclin E-Cdk2 (Fig. 2b, lane 3). PS100 or p21 had no effect on the dephosphorylation of *p*-nitrophenyl phosphate by Cdc25A (data not shown), suggesting that the inhibition of dephosphorylation of cyclin-Cdk2 was not due to non-specific inhibition of phosphatase activity.

Equal concentrations of mutant versions of p21 were added to the reaction where Cdc25A dephosphorylated cdk2 (Fig. 2B). Dephosphorylation was followed by immunoblotting with anti-phosphotyrosine antibody. The presence of equal amount of cdk2 after the incubation was shown by stripping the anti-phosphotyrosine blot and immunoblotting with anti-cdk2 rabbit polyclonal antibody. The results indicate that the p21 molecule required at least one K site and one of two Cy sites for optimal inhibition of Cdc25A action. Thus p21 with a deletion of the K site (lane 5) or a deletion of both Cy sites (lane 7) failed to inhibit Cdc25A phosphatase. We have shown that the stable association of p21 with cyclin E- or A-Cdk2 also requires at least one K site and one of two Cy sites (5). Therefore, although a peptide containing the cyclin binding motif inhibits Cdc25A activity, p21 interferes with Cdc25A activity more efficiently because it utilizes both the cyclin and cdk binding motifs to sequester the cyclin-Cdk from Cdc25A.

Mutation in the putative cyclin binding motif on the N-terminus of cdc25A affects its cyclin binding activity.

To confirm whether the RRLFF sequence on Cdc25A is responsible for binding to cyclins, we changed the LF residues to KK by site directed mutagenesis (Cdc25A2). The mutation in Cdc25A protein almost abolished its binding to cyclin E or A in vitro (Fig. 3A, lane 3). The mutation has no effect on the cyclin D1-Cdc25A or cyclin B-Cdc25A interactions. Similar effects of the mutation were observed when HeLa cell lysates were used to provide cyclin E- or A-Cdk2 (data not shown).

To investigate the effects of mutating the cyclin binding motif of Cdc25A in vivo, we transfected 293T cells with plasmids expressing Cdc25A or Cdc25A2 as GST fusion proteins (Fig. 3B). The expressed GST-Cdc25A proteins were affinity purified from the cell lysate with glutathione agarose beads. The associated cyclins E or A were detected by Western blot analysis and associated cdk2 detected by a kinase assay using histone H1 as substrate. Although equal quantities of GST (from the EBG transfection in lane 1; visible in the 30 kD area of the gel not shown in the figure), GST-Cdc25A (lane 2) and GST-Cdc25A2 (lane 3) were expressed and isolated on the glutathione agarose beads, cyclin E, A or Cdk2

could only associate with GST-Cdc25A. This observation confirms the importance of the RRLLF motif for association of Cdc25A with cyclin E- or A-Cdk2 in cells.

p21 disrupts the interaction between Cdc25A and cyclins and inhibits the dephosphorylation of Cdk2 in vivo.

p21 disrupted the association of Cyclin-cdk with Cdc25A in vitro (Fig. 1C). To investigate if this was true in vivo, 293T cells were transfected with a plasmid expressing GST or GST-Cdc25A alone or cotransfected with increasing amount of p21 expressing plasmid (Fig. 4A). The GST proteins were isolated on glutathione agarose beads and associated cyclins and cdks detected as in Fig. 3B. Cyclin E, A or Cdk2 were associated with GST-Cdc25A (lane 2) but not with GST (lane 1). When p21 was co-expressed with GST-Cdc25A (lanes 3 and 4) association of cyclins and cdks with Cdc25A was inhibited. Therefore, consistent with the results observed in vitro, overexpression of p21 in the cells disrupted the interaction between cyclin E- or A-Cdk2 and Cdc25A.

If p21 disrupted the association of Cdc25A with cyclin-cdks, it could simultaneously inhibit the dephosphorylation of cdk by Cdc25A (Fig. 4B). 293T cells were transfected with control plasmid pAHP (modified pcDNA3 for vector control; lanes 1 & 3) or pcDNA3-p21 (lanes 2 & 4). cdk2 was isolated either by immunoprecipitation with anti-p21 monoclonal antibody CP68 (lanes 1 & 2) or anti-cdk2 rabbit polyclonal antibody (lanes 3 & 4). The immunoprecipitates were immunoblotted with anti-cdk2 antibody revealing that approximately equal amounts of cdk2 were present complexed with p21 (lane 2) and free of p21 (lanes 3 and 4). Probing with anti-phosphotyrosine antibody (anti-PY) showed that the p21-complexed cdk2 (lane 2) had substantial amounts of phosphotyrosine compared to the other lanes with cdk2. Because less than 5% of the cells on a plate are transfected with the p21 plasmid, the increased phosphotyrosine is seen only when we examine the cdk2 associated with p21 (lane 2) and not when we examine the total cdk2 population from the plate (lane 4, 95% of which comes from cells without p21). Therefore p21 inhibited the removal of tyrosine phosphate from Cdk2 molecules associated with it in vivo.

Cdc25A protects cyclin-Cdk2 kinase from inhibition by p21.

Because p21 inhibited both the association of Cdc25A with cyclin-cdk2 and the phosphatase activity of Cdc25A on the kinase, we wondered if the reverse was also true: whether Cdc25A associated cyclin-cdk2 was protected from inhibition by p21. To test this, Cdc25A bound cdk2 was isolated from cell extracts by expressing GST-Cdc25A in cells and purifying the GST-Cdc25A-cdk2 complex on glutathione agarose beads (Fig. 5A). Free cyclin-cdk2 was isolated from the cell extract in parallel by immunoprecipitation with anti-cdk2 antibody. The kinase activity of these two forms of cdk2 was tested on histone H1. Quantitation of the radiolabel incorporated in the histone H1 indicated that approximately equal quantities of active kinase were present in the two precipitates (lane 1: 2400 cpm in the top panel and 3000 cpm in the bottom panel). Addition of increasing quantities of recombinant p21 to the reaction showed that at least 5 fold more p21 was required to inhibit by 50% the kinase activity of Cdc25A bound cdk2 compared to the general pool of cyclin-cdk2 (Fig. 5A, lanes 2 and 4). Further, the Cdc25A-bound cdk2 retained 30-40% residual kinase activity despite the addition of p21 at μ M concentrations (lanes 5 and 6, and data not shown). Therefore Cdc25A bound cdk2 was protected from kinase inhibition by p21.

A trivial explanation of this result could be that the GST-Cdc25A complexed histone kinase was partly composed of non-cdk2 kinase and therefore resistant to p21. To rule this out, the cell lysate was precleared with anti-cdk2 antibody before the isolation of GST-Cdc25A on glutathione agarose beads (Fig. 5B). Histone H1 kinase activity recovered with GST-Cdc25A was consistently removed by pre-clearing with anti-cdk2 antibody, suggesting that all the histone H1 kinase co-precipitated with GST-Cdc25A was due to cdk2. Therefore, the p21-resistant histone kinase associated with Cdc25A noted in Fig. 5A is cyclin-cdk2.

Cyclins cannot protect cyclin-Cdk2 kinase from inhibition by p21. We tested whether another activator of cyclin-cdk, cyclins E and D1, which were reported to be over-expressed in a significant fraction of breast cancers could also protect cyclin-cdk2 kinase from p21. In the standard kinase assay where increasing quantities of p21 is added to a reaction containing baculovirus produced cyclin A-cdk2 or cyclin E-cdk2 acting on GST-Rb as substrate, the p21 is a potent inhibitor of kinase (5). When the reaction contained excess GST-cyclin E or cyclin A (10 to 100 fold molar excess relative to p21), the inhibition curve of p21 was not changed (data not shown). Thus cyclin uncomplexed with cdk cannot competitively inhibit the association of p21 with cyclin-cdk2. Of course, in the cancer cells the

over-expressed cyclin could all be associated with cdk2, in which case the p21 resistance could be because there is much more enzyme in these cells that need to be inactivated by p21.

Based on the significant positive results obtained with Cdc25A (an activator of cyclin-cdk) we did not pursue whether another activator (CAK) interfered with p21 function. Furthermore, unlike Cdc25A, there is no evidence in the Literature that CAK is up-regulated in breast cancers.

FIGURE LEGENDS

Fig. 1 A, Association between cyclins and Cdc25 phosphatases. ^{35}S -labeled cyclins (Cyc) bound to indicated GST fusion proteins were visualized by fluorography. 0.1 x input: one-tenth of the proteins input into the reactions.

B, PS100, a peptide containing the Cy1 motif of p21, inhibits the binding between Cdc25A and cyclins E and A. The binding of 1 μg of GST-Cdc25A with ^{35}S -labeled cyclins E and A in 0.2 ml of binding reaction in the absence or presence of PS100 and mutant control PS101 peptides. Lanes 1, GST; Lanes 2-6, GST-Cdc25A. The numbers on the top represent the μM of peptide added.

C, p21 disrupts the interactions between Cdc25A and cyclins E, A and D1. 2 μl (lanes 3), 10 μl (lanes 4) and 20 μl (lanes 5) of *E. coli* lysate containing His⁶ tagged human recombinant p21 protein (approximately 100 $\mu\text{g}/\text{ml}$) were added to the 0.2 ml binding reactions between GST-Cdc25A (1 μg) and ^{35}S -labeled cyclins. Final p21 concentrations in the binding reactions are 0.05, 0.25 and 0.5 μM in lanes 3, 4 and 5, respectively. Con, 20 μl of *E. coli* lysate without His⁶-p21. Lanes 1, GST; lanes 2-6, GST-Cdc25A.

Fig. 2 A, The peptide PS100 with a Cy1 motif inhibits the removal of tyrosine phosphate from cdk2 by Cdc25A. Lane 1, no GST-Cdc25A phosphatase; Lanes 2-4, with GST-Cdc25A. 75 μM of peptides PS100 or PS101 were added as indicated on the top. Removal of tyrosine -phosphate was followed by immunoblotting with anti-phosphotyrosine (anti-PY) antibody. Cdk2-R169L levels were unchanged throughout the incubations (data not shown).

B, p21 inhibits the phosphatase activity of Cdc25A on cdk2. One cyclin binding (Cy1) site and the cdk2 binding (K) site of p21 are required for inhibition of Cdc25A action on cdk2. Lane 1: no Cdc25A. Lanes 2-8: Cdc25A with 0.2 μM of indicated GST fusion proteins, except in lane 8 where the concentration of GST was 3.6 μM . p21 Δ Cy1, p21 with the deletion of Cy 1 (p21 Δ 17-24); p21 Δ K, p21 with deletion of K site (p21 Δ 53-58); p21 Δ Cy2, p21 with deletion of Cy2 site (p21N); p21 Δ Cy1+Cy2, p21 with deletion of both cyclin binding Cy sites (p21N Δ 17-24) (for a detailed description of the mutants see ref. 5). The presence of equal amount of cdk2-R169L were shown by stripping the anti-phosphotyrosine blot and immunoblotting with anti-cdk2 rabbit polyclonal antibody (anti-cdk2).

Fig. 3 A, The mutation in the putative cyclin binding motif on the N-terminus of Cdc25A disrupts its interaction with Cyclins E and A *in vitro*. LF residues in the RRLLF (residues 10-14) sequence of Cdc25A were changed to KK in Cdc25A2. ^{35}S -labeled cyclins (Cyc) bound to 1 μg of the indicated GST fusion proteins were visualized by fluorography.

B, Mutation of cyclin binding motif of Cdc25A disrupts interaction with Cyclins E and A or cdk2 *in vivo*. 293T cells were transfected with plasmids indicated on top and expressed GST-fusion proteins purified on glutathione agarose beads. The associated proteins were analyzed by immunoblotting and kinase assay. Pon-S, Ponceau-S staining of the nitrocellulose blot showing the presence of equal amounts of GST (30 kD, not visible in the figure) and of GST-Cdc25A or GST-Cdc25A2 proteins (90 kD). I.B., immunoblot analysis with anti-cyclin E monoclonal antibody (HE12) and anti-cyclin A rabbit polyclonal antibody. Positions of Cyclins E and A are shown (Cyc E and Cyc A). The HE12 antibody reacts non-specifically with a protein slightly larger than cyclin E creating a background band present in all lanes. Kinase assay, the phosphorylation of GST-Cdc25A or GST-Cdc25A2 (GST-Cdc25A) and histone H1 (H1) by cdk2 associated with Cdc25A.

Fig. 4 A, p21 disrupts the interaction between Cdc25A and cyclins *in vivo*. 293T cells were transfected with pEBG, pEBG-CDC25A or co-transfected with pEBG-CDC25A and 2 or 5 μ g of pcDNA3-p21 plasmids (indicated on the top). The lysate of the transfected cells were incubated with glutathione agarose beads and the pulled down complexes were analyzed by immunoblotting (I.B.) and kinase assay. Pon-S, Ponceau-S staining of nitrocellulose blot shows equal quantities of GST (30 kD, not visible in the figure) and GST-fusion proteins (90 kD). For input lanes 0.01 volume of lysate used for pull down were analyzed by immunoblot analysis.

B, p21 inhibits the dephosphorylation of tyrosine phosphate of cdk2 *in vivo*. 293T cells were transfected with control plasmid pAHP (modified pcDNA3 for hemagglutinin tag) (lanes 1 & 3) or pcDNA3-p21 (lanes 2 & 4) and the immunoprecipitation were carried out with anti-p21 monoclonal antibody (CP68) (lanes 1 & 2) and anti-cdk2 rabbit polyclonal antibody (lanes 3 & 4). The immunoprecipitates were immunoblotted with anti-cdk2 antibody and then, after stripping, the same blot was probed with anti-phosphotyrosine antibody (anti-PY). cdk2 migrates as a single band under the conditions of our electrophoresis. The arrows point to background bands that are not related to cdk2.

Fig. 5 A, Cdc25A protects cyclin-cdk2 from the inhibition by p21. For each lane in the top panel, cdk2 associated with GST-Cdc25A was isolated from 2.5 million 293T cells transfected with EBG-Cdc25A by affinity purification on glutathione agarose beads. For each lane in the bottom panel total cdk2 was isolated from 5 million 293T cell by immunoprecipitation with anti-cdk2 antibody. Kinase reactions were carried out with Cdc25A associated cdk2 (Cdc25A assoc., top) and anti-cdk2 immunoprecipitate (α -cdk2 I.P., bottom) using histone H1 and γ 32P ATP. Lane 1, base-line kinase reaction: 32P incorporated into H1 was 2400 cpm in the top panel and 3000 cpm in the bottom panel. Lanes 2-6: indicated concentrations of p21 added to the kinase reactions.

B, The histone kinase associated with GST-Cdc25A is cyclin-Cdk2. Extract of 293T cells transfected with pEBG-Cdc25A was immunodepleted by 3 cycles of immunoprecipitation with anti-Cdk2 polyclonal antibody. GST-Cdc25A associated kinase was isolated by affinity purification on glutathione agarose beads (lanes 1 and 2) or total cdk2 isolated by immunoprecipitation with anti-Cdk2 antibody (lanes 3 and 4) from untreated (lanes 1 and 3) or immunodepleted (lanes 2 and 4) extracts. Kinase reactions were carried with the precipitates using histone H1 and γ 32P ATP as substrate and an autoradiogram of the phosphorylated histone is shown.

Fig. 6 Model showing that p21 and Cdc25A utilize similar Cy motifs to compete for the same binding site on cyclin. K is the cdk2 binding motif of p21.






Figure 1




Figure 2




Figure 3





Figure 4




Figure 5





Figure 6



CONCLUSIONS

Our results confirm previous reports that Cdc25A forms stable complex with cyclins E, A, D1 and B (Fig. 1A) (11, 13, 14). It is known that p53 induced Cdk inhibitor p21 interacts with cyclins using a conserved Cy1 motif (5, 20, 21). The consensus motif consists of two basic amino acids followed by two residues with non-polar side chain (RRLFG). Cdc25A also contains a similar amino acid sequence on residues 10-14 (RRLLF) and our competition experiments with Cy1 containing peptide PS100 and full length p21 shows that Cdc25A probably uses a Cy like motif to associate with cyclins (Fig. 1B and C). PS100 inhibits the interaction between Cdc25A and cyclins E and A (Fig. 1B), whereas p21 inhibits the interaction of Cdc25A with all three cyclins.

By site directed mutagenesis we confirmed that the Cy motif of Cdc25A is used to associate with cyclins *in vitro* as well as *in vivo*. Several biologically important substrates (e.g. p107, Rb, p130, E2F1) and inhibitors of cyclin-Cdk complex use this motif to interact with cyclins. Here we show that an activator of cyclin-Cdk2 also uses a similar motif for its interaction with cyclins.

Our results in addition show that p21 disrupts the association between Cyclin-Cdk and Cdc25A. By doing so, p21 blocks the removal of the inhibitory phosphate groups on Cdk2 by Cdc25A. So, besides the well-recognized function of inhibiting the cyclin-Cdk kinases, p21 also prevents the activation of these kinases by Cdc25A, providing a second mechanism for disrupting the positive feedback loop between Cdc25A and cyclin E-Cdk2.

The antagonism of Cdc25A action implies that whenever p21 is induced in a cell, the amount of phosphotyrosine on the cdk2 or cdk4 molecules should increase. We demonstrate this by transfecting a plasmid expressing p21 into cells (Fig. 4B).

We also show that Cdc25A can protect Cyclin-Cdk2 complex from the inhibitory action of p21 (Fig. 5). This result is particularly impressive because p21 is a potent inhibitor of cyclin-cdks that associates with kinase with high affinity using both Cy-cyclin and K-cdk interactions (Fig. 6). In contrast, the association of Cdc25A with cyclin-cdks only utilizes the relatively weaker Cy-cyclin interaction. Despite this apparent disadvantage, Cdc25A successfully blocked the inhibitory action of p21. This is the first example of a cellular molecule which plays such a role vis-a-vis the p21 class of cdk inhibitors. The Myc oncoprotein directly stimulates the expression of Cdc25A (18) and so Myc transformed cells have elevated levels of Cdc25A. Overexpression of Cdc25A could explain why Myc transformed cells are resistant to p21 (22).

We have made significant progress in the project in this year and the results described above are now published as part of Ref. 23. Cdc25A, a phosphatase essential for G1-S transition, associates with, dephosphorylates and activates the cell-cycle kinase cyclin E-cdk2. p21 and p27 are cdk inhibitors induced by growth suppressive signals such as p53 and TGF β . We have identified a cyclin binding motif near the N terminus of Cdc25A that is similar to the cyclin binding Cy1 (or LFG) motif of p21/p27 family of cdk inhibitors and separate from the catalytic domain. Mutations in this motif disrupt the association of Cdc25A with cyclin E- or cyclin A-cdk2 *in vitro* and *in vivo*. A peptide based on the Cy1 motif of p21 competitively disrupts the association of Cdc25A with cyclin-cdks and inhibits the de-phosphorylation of the kinase. p21 inhibits Cdc25A/cyclin-cdk2 association and the dephosphorylation of cdk2. Conversely, Cdc25A, which is itself an oncogene up-regulated by the Myc oncogene, associates with cyclin-cdk, protects it from inhibition by p21. These results describe a mechanism by which the Myc- or Cdc25A-induced oncogenic and p53- or TGF β -induced growth-suppressive pathways could counterbalance each other by competing for the cyclin-cdks. Thus activation of Myc (and Cdc25A) may explain why 10% of the breast cancers surveyed demonstrate increased levels of p21 in the nuclei and yet fail to stop proliferating (unpublished results). These results also support the possibility the Cy motif-mimetic chemicals developed for pharmacology of breast cancers may be quite potent because of the additional function of preventing the activation of G1-S cyclin-cdks by the Cdc25A phosphatase. Finding the structural determinants of a functional Cy motif (Task 5, year 4) will therefore be an useful contribution towards this end.

REFERENCES

1. Leiter LM, Chen J, Marathe T, Tanaka M, Dutta A. (1996) Loss of transactivation and trasrepression function, and not RPA binding, alters growth suppression by p53. *Oncogene* **12**, 2661-2668.
2. Deng CX, Zhang PM, Harper JW, Elledge SJ, Leder P. (1995) Mice lacking p21(cip1/waf1) undergo normal development, but are defective in G1 checkpoint control. *Cell* **82**, 675-684.
3. Waldman T, Kinzler KW, Vogelstein B. (1995) P21 is necessary for the p53-mediated g(1) arrest in human cancer cells. *Cancer Research* **55**, 5187-5190.
4. Chen J, Jackson PK, Kirschner MW, Dutta A. (1995) Separate domains of p21 involved in the inhibition of cdk kinase and PCNA. *Nature* **374**, 386-388.
5. Chen J, Saha P, Kornbluth S, Dynlacht B, Dutta A. (1996) Cyclin-binding motifs are essential for the function of p21CIP1. *Mol Cell Biol* **16**, 4673-4682.
6. Russo AA, Jeffry PD, Patten AK, Massague J, Pavletich NP. (1996) Crystal structure of the p27(Kip1) cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. *Nature* **382**, 325-331.
7. Shiohara M, el DW, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, Vogelstein B, Koeffler HP. (1994) Absence of WAF1 mutations in a variety of human malignancies. *Blood* **84**, 3781-4.
8. Gu Y, Rosenblatt J, Morgan DO. (1992) Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. *EMBO J* **11**, 3995-4005.
9. Sandhu K, Reed SI, Richardson H, Russell P. (1990) Human homolog of fission yeast cdc25 mitotic inducer is predominantly expressed in G2. *proc Natl Acad Sci USA* **87**, 5139-5143.
10. Nagata A, Igarashi M, Jinno S, K S, Okayama H. (1991) An additional homolog of the fission yeast cdc25+ gene occurs in humans and is highly expressed in some cancer cells. *New Biol.* **3**, 959-967.
11. Galaktionov K, Beach D. (1991) Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. *Cell* **67**, 1181-1194.
12. Hoffmann I, Clarke P, Marcote M, Karsenti E, Draetta G. (1993) Phosphorylation and activation of human cdc25C by cdc2-cyclin B and its involvement in the self-amplification of MPF at mitosis. *EMBO J* **12**, 53-63.
13. Hoffmann I, Draetta G, Karsenti E. (1994) Activation of the phosphatase activity of human cdc25A by a cdc2-cyclin E dependent phosphorylation at the G1-S transition. *EMBO J* **13**, 4302-4310.
14. Jinno S, Suto K, Nagata A, al. e. (1994) cdc25A is a novel phosphatase functioning early in the cell cycle. *EMBO J.* **13**, 1549-1556.
15. Strausfeld UP, Howell M, Rempel R, Maller JL, Hunt T, Blow JJ. (1994) Cip1 blocks the initiation of dna replication in xenopus extracts by inhibition of cyclin-dependent kinases. *Current Biology* **4**, 876-883.
16. Zheng XF, Ruderman JV. (1993) Functional analysis of the P box, a domain in cyclin B required for the activation of Cdc25. *Cell* **75**, 155-64.
17. Galaktionov K, Lee A, Eckstein J, Draetta G, Meckler J, Loda M, Beach D. (1996) CDC25 phosphatase as potential human oncogene. *Science* **269**, 1575-1577.
18. Galaktionov K, Chen X, Beach D. (1996) Cdc25A cell-cycle phosphatase as a target of c-myc. *Nature* **382**, 511-517.
19. Mayer BJ, Hirai H, Sakai R. (1995) Evidence that SH2 domains promote processive phosphorylation by protein tyrosine kinase. *Curr. Biol.* **5**, 296-305.
20. Chen IT, Akamatsu M, Smith ML, Lung FDT, Duba D, Roller PP, Forence AJ, O'Conner PM. (1996) Chracterization of p21(Cip1/Waf1) peptide domains required for cyclin E/cdk2 and PCNA interaction. *Oncogene* **12**, 595-607.
21. Lin J, Reichner C, Wu X, Levine AJ. (1996) Analysis of wild-type and mutant p21(Waf1) gene activities. *Mol. Cell. Biol.* **16**, 1786-1793.
22. Hermeking H, Funk JO, Reichert M, Rllwart JW, Eick D. (1995) Abrogation of p53-induced cell cycle arrest by c-Myc: evidence for an inhibitor of p21-WAF1/CIP1/SDI1. *Oncogene* **11**, 1409-1415.

23. Saha P, Eichbaum Q, Silberman ED, Mayer BJ, Dutta A. (1997) p21/CIP1 and Cdc25A: competition between an inhibitor and an activator of cyclin-dependent kinases. *Mol. Cell. Biol.* **17**, 4338-4345.

p21^{CIP1} and Cdc25A: Competition between an Inhibitor and an Activator of Cyclin-Dependent Kinases

PARTHA SAHA,¹ QUENTIN EICHBAUM,¹ E. D. SILBERMAN,² BRUCE J. MAYER,²
AND ANINDYA DUTTA^{1*}

Department of Pathology, Brigham and Women's Hospital,¹ and Howard Hughes Medical Institute, Department of Microbiology and Molecular Genetics, Children's Hospital,² Harvard Medical School, Boston, Massachusetts 02115

Received 10 February 1997/Returned for modification 30 March 1997/Accepted 29 April 1997

Cdc25A, a phosphatase essential for G₁-S transition, associates with, dephosphorylates, and activates the cell cycle kinase cyclin E-cdk2. p21^{CIP1} and p27 are cyclin-dependent kinase (cdk) inhibitors induced by growth-suppressive signals such as p53 and transforming growth factor β (TGF- β). We have identified a cyclin binding motif near the N terminus of Cdc25A that is similar to the cyclin binding Cy (or RR LFG) motif of the p21^{CIP1} family of cdk inhibitors and separate from the catalytic domain. Mutations in this motif disrupt the association of Cdc25A with cyclin E- or cyclin A-cdk2 in vitro and in vivo and selectively interfere with the dephosphorylation of cyclin E-cdk2. A peptide based on the Cy motif of p21 competitively disrupts the association of Cdc25A with cyclin-cdks and inhibits the dephosphorylation of the kinase. p21 inhibits Cdc25A-cyclin-cdk2 association and the dephosphorylation of cdk2. Conversely, Cdc25A, which is itself an oncogene up-regulated by the Myc oncogene, associates with cyclin-cdk and protects it from inhibition by p21. Cdc25A also protects DNA replication in *Xenopus* egg extracts from inhibition by p21. These results describe a mechanism by which the Myc- or Cdc25A-induced oncogenic and p53- or TGF- β -induced growth-suppressive pathways counterbalance each other by competing for cyclin-cdks.

The eukaryotic cell division cycle is regulated by various phosphorylation and dephosphorylation events. The key phosphorylation events during the cell cycle are carried out by cyclin-dependent kinases (cdks) (9, 20, 31, 35, 39). The cdks are positively regulated by the binding of appropriate cyclin molecules (7, 10, 32) and by stimulatory phosphorylation by cdk-activating kinase (CAK) at a conserved threonine residue (Thr-160 of cdk2) (37). The activities of cdks are also modulated by inhibitory mechanisms. There are two families of cdk inhibitors which negatively regulate kinase activities (29). The first family consists of p21, p27, and p57 and acts on a wide range of cyclin-cdk complexes. The second group includes p15, p16, and p18 and inhibits only cyclin D-dependent G₁ kinases cdk4 and cdk6. Phosphorylation of conserved threonine and tyrosine residues near the ATP binding sites of cdks (Thr-14 and Tyr-15 on cdk2) (14) by wee1 and mik1 protein kinases is another important mechanism employed to keep the cdks inactive. In the fission yeast *Schizosaccharomyces pombe* there is only one known type of phosphatase, Cdc25, which removes the inhibitory phosphate groups from Cdc2 (CDC28) during G₁-S and G₂-M transitions (28). In human and murine cells, there are three known CDC25 genes (CDC25A, CDC25B, and CDC25C) (11, 30, 34). The three phosphatases share approximately 40 to 50% homology at the amino acid level. CDC25C and CDC25A function at G₂-M and G₁-S transitions during the human cell cycle, respectively (17–19). Cdc25C dephosphorylates Cdc2 in the Cdc2-cyclin B complex and activates its histone H1 kinase. The phosphatase activities of Cdc25 proteins are, in turn, regulated by phosphorylation. Cdc25C is phosphorylated and activated by Cdc2-cyclin B, creating a positive feedback loop between Cdc25C and Cdc2-cyclin B function at the G₂-M transition (17, 40, 43). A similar loop occurs

at the G₁-S transition between Cdc25A and the Cdk2-cyclin E complex (18). Cdc25A dephosphorylates and activates the kinase activity of the Cdk2-cyclin E complex, which, in turn, phosphorylates and stimulates the phosphatase activity of Cdc25A. Recently it was shown that Cdc25A and Cdc25B act as oncogenes (13). They transform primary mouse embryonic fibroblasts in cooperation with the Ras oncogene and are over-expressed in almost a third of breast cancers. It has also been reported that the proto-oncogene product c-Myc directly stimulates Cdc25A expression (12).

cdk inhibitor p21 is transcriptionally induced by tumor suppressor protein p53 (8). Like other cdk inhibitors, the biological activities of p21 depend on its ability to inhibit cyclin-cdk kinases (4). p21 also interacts with and inhibits the DNA replication factor proliferating cell nuclear antigen (4, 23, 26, 42). This activity could be important for inhibiting DNA replication following DNA damage (26, 36, 40). However, the cdk inhibitory activity, rather than the proliferating cell nuclear antigen binding activity, is required to block G₁-S transition (4, 26). Unlike the p16-p15-p18 class of cdk inhibitors, in which the inhibitor molecules compete with cyclin D for the association with cdk4 or cdk6, the p21-p27-p57 family of inhibitors interacts with cyclin-cdk complexes (29). We and others have shown that p21 interacts directly with cyclins and that the association is important for the activity of p21 (3, 5, 25). The interaction takes place through a conserved region near the N terminus (amino acids 17 to 24), which we call cyclin binding motif 1 (Cy1). p21 has a second redundant weak cyclin binding motif (Cy2) near its C terminus. The inhibitor molecule has a separate cdk2 binding site (K) on amino acids 53 to 58, and optimum inhibition requires at least one such Cy site and the K site. The Cy1 motif is present on other inhibitors of cdk, e.g., p27 and p57 and the substrates p107, p130, and E2F1, all of which associate stably with cyclin-cdks (5, 15, 21, 24, 26, 44).

In this study, we identified a cyclin binding motif near the N terminus of Cdc25A that is similar to the Cy1 motif of p21. Mutations in this motif disrupt the interactions of Cdc25A with

* Corresponding author. Mailing address: Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA 02115. Phone: (617) 278-0468. Fax: (617) 732-7449. E-mail: adutta@bustoff.bwh.harvard.edu.

cyclin E- or A-cdk2 in vitro and in vivo. A peptide based on the Cy1 motif of p21 (5) competitively disrupts the association of Cdc25A with cyclin-cdks and inhibits the dephosphorylation of the kinase. p21 inhibits Cdc25A-cyclin-cdk2 interaction and the dephosphorylation of cdk2. Conversely, Cdc25A associates with cyclin-cdk and protects it from inhibition by p21. This is the first report of a competitive antagonism between cdk inhibitors like p21 and cdk stimulators like Cdc25A and suggests that Cy motif-cyclin interactions are important in the regulation and activity of cyclin-cdks in diverse ways.

MATERIALS AND METHODS

Protein expression in bacteria and binding reactions. pGEX-2T plasmids (Pharmacia) containing human CDC25A cDNAs (11, 34) were used to express the glutathione *S*-transferase (GST) fusion proteins in *Escherichia coli* BL21. The site-directed mutagenesis was performed as previously described (22), and the mutant CDC25A was also cloned into pGEX-2T for expression as a GST fusion protein. The affinity purification of the fusion proteins over glutathione agarose was carried out as described before (5). PS100 (ACRRLFGPVDSE) contains the Cy1 motif of p21, and in the control peptide PS101 (ACRRLKKPVDSE) the FG residues are mutated to KK (underlined) (5). ³⁵S-labeled cyclins were prepared in coupled in vitro transcription and translation reactions. The binding reactions were carried out in a total volume of 0.2 ml containing about 1 µg of GST fusion proteins on glutathione agarose beads and ³⁵S-labeled cyclins in buffer A7.4 (20 mM Tris-HCl [pH 7.4], 1 mM EDTA, 25 mM NaCl, 1 mM dithiothreitol [DTT], 10% glycerol, 0.01% Nonidet P-40) for 1 h at 4°C on a rotating wheel (4, 5).

Phosphatase assay. cdk2 with Arg-169 mutated to Leu (R169L) is partially active as a kinase, and when produced in insect cells it has a significant amount of phosphorylation on Tyr-15 (36a). cdk2-R169L was expressed along with GST-cyclin E in insect cells and GST-cyclin E-cdk2-R169L was purified. GST-cyclin E-cdk2-R169L (with tyrosine phosphate) was used as the substrate in the in vitro phosphatase reaction (see Fig. 2). Anti-phosphotyrosine (anti-PY) monoclonal antibody and anti-cdk2 polyclonal antibodies were from Upstate Biotechnology Incorporated. The phosphatase reactions were carried out for 15 min at 30°C in a total volume of 20 µl containing 1 µg of GST-cyclin E-cdk2-R169L and 0.5 µg of GST-Cdc25A in 50 mM Tris-HCl (pH 8.0)-50 mM NaCl-2 mM DTT. The reactions were stopped by adding sodium dodecyl sulfate (SDS) sample buffer, and the products were analyzed by Western blot analysis.

Transfection, immunoprecipitation, and pull-down. Wild-type and mutant CDC25A cDNAs were cloned into the eukaryotic GST fusion protein expression vector pEBG (27), and the transfections into human kidney 293T cells were carried out by the Ca₃(PO₄)₂ method (22). The transfected cells were harvested after 2 days and lysed in 50 mM Tris-HCl, pH 7.4, containing 5 mM EDTA, 0.1% Triton X-100, 1 mM DTT, 250 mM NaCl, 50 mM NaF, 1 mM sodium vanadate, 1 mM phenylmethylsulfonyl fluoride, 2 µg of aprotinin/ml, 0.5 µg of leupeptin/ml, and 1 µg of pepstatin A/ml. A volume of lysate containing 2 mg of total protein was used for the immunoprecipitation or pull-down reactions.

Kinase assay. Kinase reaction was carried out at 30°C for 10 min in 50 mM Tris-HCl, pH 7.5, containing 10 mM MgCl₂, 1 mM DTT, 50 µM ATP, 1 µg of histone H1, and 2 µCi of [γ-³²P]ATP in a total volume of 20 µl. The reaction was stopped by the addition of SDS-polyacrylamide gel electrophoresis sample buffer, and the products were analyzed by SDS-polyacrylamide gel electrophoresis and autoradiography.

DNA replication. Replication of sperm chromatin in activated *Xenopus* egg extract was carried out in the presence of [α-³²P]dATP for 3 h at 23°C, and the products were analyzed by gel electrophoresis (4). GST, GST-Cdc25A, or GST-Cdc25A2 was preincubated with the *Xenopus* egg extract for 10 min at 23°C before adding p21 and DNA and continuing with the replication reaction.

RESULTS

Stable complex formation between cyclins and Cdc25 phosphatases. To investigate the interactions between Cdc25 phosphatases and cyclins, Cdc25A, -B, and -C proteins were produced as GST fusion proteins in *E. coli* and bound to glutathione agarose beads from the bacterial lysates. Cyclins A, B, D1, and E were prepared as ³⁵S-labeled proteins in a coupled in vitro transcription and translation reaction with rabbit reticulocyte lysate. Results of the pull-down assays using glutathione beads containing equal amounts of GST fusion proteins and ³⁵S-labeled cyclins are shown in Fig. 1A. None of the cyclins bound to GST. Cyclins E and A bound only to GST-Cdc25A, whereas cyclin B bound to GST-Cdc25A and GST-




FIG. 1. Association between cyclins and Cdc25 phosphatases. (A) ³⁵S-labeled cyclins (Cyc) bound to indicated GST fusion proteins were visualized by fluorography. 0.1 input, 1/10 of the proteins input into the reaction mixtures. (B) PS100, a peptide containing the Cy1 motif of p21, inhibits the binding between Cdc25A and cyclins E and A. The binding of 1 µg of GST-Cdc25A with ³⁵S-labeled cyclins E and A in 0.2 ml of binding reaction mixture in the absence or presence of PS100 and mutant control PS101 peptides is shown. Lanes 1, GST; lanes 2 to 6, GST-Cdc25A. The numbers at the top of the panel are the micromolar concentrations of the peptide added. (C) p21 disrupts the interactions between Cdc25A and cyclins E, A, and D1. Two microliters (lanes 3), 10 µl (lanes 4), and 20 µl (lanes 5) of *E. coli* lysate containing His₆-tagged human recombinant p21 protein (approximately 100 µg/ml) were added to the 0.2-ml binding reactions between GST-Cdc25A (1 µg) and ³⁵S-labeled cyclins. Final p21 concentrations in the binding reaction mixtures are 0.05, 0.25, and 0.5 µM in lanes 3, 4 and 5, respectively. Con, 20 µl of *E. coli* lysate without His₆-tagged p21. Lanes 1, GST; lanes 2 to 6, GST-Cdc25A.

Cdc25C. In this assay, cyclin D1 bound to all GST-fused Cdc25 proteins.

Cdc25A contains a putative cyclin binding motif on the N terminus similar to the Cy1 motif of p21^{CIP1}. p21 has two




FIG. 2. (A) The peptide PS100 with a Cy1 motif inhibits the removal of tyrosine phosphate from cdk2 by Cdc25A. Lane 1, no GST-Cdc25A phosphatase; lanes 2 to 4, GST-Cdc25A. Peptide PS100 or PS101 (75 μ M) was added as indicated. Removal of tyrosine phosphate was followed by immunoblotting with anti-PY antibody. cdk2-R169L levels were unchanged throughout the incubations (data not shown). (B) p21 inhibits the phosphatase activity of Cdc25A on cdk2. One Cy1 site and the cdk2 binding K site of p21 are required for inhibition of Cdc25A action on cdk2. Lane 1, no Cdc25A; lanes 2 to 8, Cdc25A with 0.2 μ M indicated GST fusion proteins, except in lane 8 where the concentration of GST was 3.6 μ M. p21 Δ Cy1, p21 with the deletion of Cy1 (p21 Δ 17–24); p21 Δ K, p21 with deletion of the K site (p21 Δ 53–58); p21 Δ Cy2, p21 with deletion of the Cy2 site (p21 Δ N); p21 Δ Cy1+Cy2, p21 with deletion of both Cy sites (p21 Δ 17–24) (for a detailed description of the mutants, see reference 5). The presence of equal amounts of cdk2-R169L was shown by stripping the antiphosphotyrosine blot and immunoblotting with anti-cdk2 rabbit polyclonal antibody (anti-cdk2).

cyclin binding motifs, Cy1 (amino acids 17 to 24) and Cy2 (amino acids 152 to 158), and one cdk2 binding site, K (amino acids 53 to 58). p27, p57, p107, p130, and E2F1 use a similar motif to interact with cyclin E. The important amino acid residues in the motif are RRLFG. A 12-amino-acid-long peptide (PS100) derived from the Cy1 region of p21 interrupts the interaction between p21 and cyclin E or cyclin A (5).

Interestingly, human Cdc25A protein contains a similar amino acid sequence at residues 10 to 14 (RRLFF), and we hypothesized that this sequence is used for the interaction with cyclins. To test this we investigated the effect of PS100 on the association of Cdc25A with cyclins. Figure 1B shows that when pull-down assays were carried out with GST-Cdc25A and 35 S-labeled cyclin E or A in the presence of increasing amounts of PS100 peptide, Cdc25A-cyclin interaction was inhibited. A mutant peptide, PS101, in which the LF residues are changed to KK, did not affect the interaction. Therefore, a Cy1-like motif was important for the interaction of Cdc25A with cyclins E or A.

If Cdc25A uses a Cy1-like motif to associate with cyclins, we expect full-length p21 protein containing two Cy motifs to also inhibit the interaction of cyclins with Cdc25A. Bacterial lysates containing recombinant p21 were indeed found to inhibit the Cdc25A-cyclin association (Fig. 1C, lanes 3 to 5).

Effects of p21^{CIP1} and its derivatives on the phosphatase activity of Cdc25A. Cdc25A removes the inhibitory phosphate groups present on Thr-14 and Tyr-15 of cdk2. We tested the phosphatase activity of Cdc25A on derivatives of cdk2 which are phosphorylated on Tyr-15, the removal of phosphate being followed by immunoblotting with anti-PY antibody (Fig. 2A, lane 2). cdk2 levels (as detected by immunoblotting with anti-cdk2 antibody) were unchanged throughout the incubations (data not shown). The Cy1 motif-containing peptide PS100

inhibited the phosphatase activity of Cdc25A on cyclin-cdk2 (Fig. 2, lane 3) compared to the minimal inhibition by the mutant peptide PS101 (lane 4). A 400-fold-lower concentration of p21 (compared to PS100) inhibited the phosphatase activity of Cdc25A on cyclin E-cdk2 (Fig. 2B, lane 3). PS100 or p21 had no effect on the dephosphorylation of *p*-nitrophenyl phosphate by Cdc25A (data not shown), suggesting that the inhibition of dephosphorylation of cyclin-cdk2 was not due to nonspecific inhibition of phosphatase activity.

Equal concentrations of mutant versions of p21 were added to the reaction mixture in which Cdc25A dephosphorylated cdk2 (Fig. 2B). Dephosphorylation was followed by immunoblotting with anti-PY antibody. The presence of equal amounts of cdk2 after the incubation was shown by stripping the antiphosphotyrosine blot and immunoblotting with anti-cdk2 rabbit polyclonal antibody. The results indicate that the p21 molecule required at least one K site and one of two Cy sites for optimal inhibition of Cdc25A action. Thus, p21 with a deletion of the K site (lane 5) or a deletion of both Cy sites (lane 7) failed to inhibit Cdc25A phosphatase. We have shown that the stable association of p21 with cyclin E- or A-cdk2 also requires at least one K site and one of two Cy sites (5). Therefore, although a peptide containing the cyclin binding motif inhibits Cdc25A activity, p21 interferes with Cdc25A activity more efficiently because it utilizes both the cyclin and cdk binding motifs to sequester the cyclin-cdk from Cdc25A.

Mutation in the putative cyclin binding motif on the N terminus of Cdc25A affects its cyclin binding activity. To confirm whether the RRLFF sequence on Cdc25A is responsible for binding to cyclins, we changed the LF residues to KK by site-directed mutagenesis (Cdc25A2). The mutation in the Cdc25A protein almost abolished its binding to cyclin E or A in vitro (Fig. 3A, lane 3). The mutation had no effect on the cyclin D1-Cdc25A or cyclin B-Cdc25A interactions. Similar effects of the mutation were observed when HeLa cell lysates were used to provide cyclin E- or cyclin A-Cdk2 (data not shown).

We tested the effect of the mutation on the phosphatase activity of Cdc25A. When *p*-nitrophenyl phosphate was used as substrate, equal amounts of GST-Cdc25A and GST-Cdc25A2 had similar activities (data not shown). On the other hand, the mutation in the cyclin binding motif of GST-Cdc25A decreased its phosphatase activity on tyrosine-phosphorylated cdk2 (Fig. 3B). Removal of the phosphate group was followed by the addition of anti-PY antibody, and the presence of equal amounts of cdk2 in the lanes was shown by stripping the antiphosphotyrosine blot and immunoblotting with anti-cdk2 antibody. As shown in Fig. 3B, GST-Cdc25A removes the tyrosine phosphate group from cdk2 (lanes 2 and 3) whereas the same amount of mutant GST-Cdc25A (Cdc25A2) does not do so (lanes 4 and 5). Therefore, the cyclin binding motif of Cdc25A is important for its phosphatase activity on cdk2.

To investigate the effects of mutating the cyclin binding motif of Cdc25A in vivo, we transfected 293T cells with plasmids expressing Cdc25A or Cdc25A2 as GST fusion proteins (Fig. 3C). The expressed GST-Cdc25A proteins were affinity purified from the cell lysate with glutathione agarose beads. The associated cyclins E or A were detected by Western blot analysis, and associated cdk2 was detected by both Western blot analysis and kinase assay using histone H1 as substrate. Although equal quantities of GST (from the pEBG transfection in Fig. 3C, lane 1; visible in the 30 kDa area of the gel but not shown in the figure), GST-Cdc25A (lane 2), and GST-Cdc25A2 (lane 3) were expressed and isolated on the glutathione agarose beads, cyclin E, cyclin A, or cdk2 could only associate with GST-Cdc25A. This observation confirms the




FIG. 3. (A) The mutation in the putative cyclin binding motif near the N terminus of Cdc25A disrupts its interaction with cyclins E and A in vitro. LF residues in the RRLLF (residues 10 to 14) sequence of Cdc25A were changed to KK in Cdc25A2. 35 S-labeled cyclins (Cyc) bound to 1 μ g of the indicated GST fusion proteins were visualized by fluorography. 0.1 input, 1/10 of the proteins input into the reactions. (B) Mutation of the Cy motif of Cdc25A inactivates its phosphatase activity on cdk2. Lane 1, no GST-Cdc25A phosphatase; lanes 2 and 3, GST-Cdc25A; lanes 4 and 5, GST-Cdc25A2. The numbers at the top indicate micrograms of the enzymes added. Removal of tyrosine phosphate was followed by Western blot analysis with anti-PY antibody. The presence of equal amounts of Cdk2-R169L in each reaction mixture was shown by stripping the anti-phosphotyrosine blot and immunoblotting with anti-Cdk2 rabbit polyclonal antibody (anti-Cdk2). Equal amounts of GST-Cdc25A and GST-Cdc25A2 have equivalent phosphatase activity towards the nonspecific phosphatase substrate *p*-nitrophenyl phosphate. (C) Mutation of Cy motif of Cdc25A disrupts interaction with cyclins E and A or cdk2 in vivo. 293T cells were transfected with plasmids indicated at top, and expressed GST-fusion proteins were purified on glutathione agarose beads. The associated proteins were analyzed by immunoblotting and kinase assay. Ponceau-S (Pon-S) staining of the nitrocellulose blot showing the presence of equal amounts of GST (30 kDa, not visible in the figure) and of GST-Cdc25A or GST-Cdc25A2 proteins (90 kDa). The immunoblot (I.B.) analyses were performed with anti-cyclin E monoclonal antibody (HE12), anti-cyclin A rabbit polyclonal antibody, or anti-Cdk2 rabbit polyclonal antibody (Upstate Biotechnology Inc.). Positions of cyclin E, cyclin A, and Cdk2 are shown (Cyc E, Cyc A, and Cdk2). The results of the kinase assay show the phosphorylation of GST-Cdc25A or GST-Cdc25A2 (GST-Cdc25A) and histone H1 (H1) by cdk2 associated with the glutathione beads.

importance of the RRLLF motif for the association of Cdc25A with cyclin E- or A-cdk2 in cells.

p21^{Cip1} disrupts the interaction between Cdc25A and cyclins and inhibits the dephosphorylation of cdk2 in vivo. p21 disrupted the association of cyclin-cdk with Cdc25A in vitro (Fig. 1C). To investigate if this was true in vivo, 293T cells were transfected with a plasmid expressing GST or GST-Cdc25A alone or cotransfected with increasing amounts of p21-expressing plasmid (Fig. 4A). The GST proteins were isolated on glutathione agarose beads, and associated cyclins and cdk2 were detected as described for Fig. 3C. Cyclin E, cyclin A, or cdk2 associated with GST-Cdc25A (Fig. 4A, lane 2) but not with GST (lane 1). When p21 was coexpressed with GST-Cdc25A (lanes 3 and 4), the association of cyclins and cdk2 with Cdc25A was inhibited. Therefore, consistent with the results observed in vitro, overexpression of p21 in the cells disrupted the interaction between cyclin E- or cyclin A-cdk2 and Cdc25A.

If p21 disrupted the association of Cdc25A with cyclin-cdk2, it could simultaneously inhibit the dephosphorylation of cdk2 by Cdc25A (Fig. 4B). 293T cells were transfected with control plasmid pAHP (modified pcDNA3 for vector control; lanes 1 and 3) or pcDNA3-p21 (lanes 2 and 4). cdk2 was isolated by immunoprecipitation with either anti-p21 monoclonal antibody CP68 (lanes 1 and 2) or anti-cdk2 rabbit polyclonal antibody (lanes 3 and 4). The immunoprecipitates were immu-

noblotted with anti-cdk2 antibody, revealing that approximately equal amounts of cdk2 were present complexed with p21 (Fig. 4B, lane 2) and in the anti-cdk2 immunoprecipitates (lanes 3 and 4). Probing with anti-PY antibody showed that the p21-complexed cdk2 (lane 2) had substantial amounts of phosphotyrosine compared to the other lanes with cdk2. Because less than 5% of the cells on a plate were transfected with the p21 plasmid, the increased phosphotyrosine was seen only when we examined the cdk2 associated with p21 (lane 2) and not when we examined the total cdk2 population from the plate (lane 4) (95% of which comes from cells without p21). Therefore p21 inhibits the removal of tyrosine phosphate from cdk2 molecules associated with it in vivo.

Cdc25A protects cyclin-cdk2 kinase from inhibition by p21. Because p21 inhibited both the association of Cdc25A with cyclin-cdk2 and the phosphatase activity of Cdc25A on the kinase, we wondered if the reverse was also true, i.e., whether Cdc25A-associated cyclin-cdk2 was protected from inhibition by p21. To test this, Cdc25A-bound cdk2 was isolated from cell extracts by expressing GST-Cdc25A in cells and purifying the GST-Cdc25A-cdk2 complex on glutathione agarose beads (Fig. 5A). Total cyclin-cdk2 was isolated from the cell extract in parallel by immunoprecipitation with anti-cdk2 antibody. The kinase activities of these two forms of cdk2 were tested on histone H1. Quantitation of the radiolabel incorporated into histone H1 indicated that approximately equal quantities of




FIG. 4. (A) p21 disrupts the interaction between Cdc25A and cyclins in vivo. 293T cells were transfected with pEBG or pEBG-CDC25A or were cotransfected with pEBG-CDC25A and 2 or 5 μ g of pcDNA3-p21 plasmids (indicated at the top). The lysates of the transfected cells were incubated with glutathione agarose beads, and the pulled-down complexes were analyzed by immunoblotting (I.B.) and kinase assay. Ponceau-S (Pon-S) staining of nitrocellulose blot shows equal quantities of GST (30 kDa, not visible in the figure) and GST-fusion proteins (90 kDa). For input lanes, 0.01 volumes of lysate used for pull down were analyzed by immunoblot analysis. (B) p21 inhibits the dephosphorylation of tyrosine phosphate of cdk2 in vivo. 293T cells were transfected with control plasmid pAHP (modified pcDNA3 for hemagglutinin tag) (lanes 1 and 3) or pcDNA3-p21 (lanes 2 and 4), and immunoprecipitations were carried out with anti-p21 monoclonal antibody (CP68) (lanes 1 and 2) and anti-cdk2 rabbit polyclonal antibody (lanes 3 and 4). The immunoprecipitates were immunoblotted with anti-cdk2 antibody, and then, after stripping, the same blot was probed with anti-PY antibody. cdk2 migrates as a single band under the conditions of our electrophoresis.

active kinase were present in the two precipitates (Fig. 5A, lane 1, 2,400 [top] and 3,000 cpm [bottom]). The addition of increasing quantities of recombinant p21 to the reaction mixture showed that at least fivefold more p21 was required to inhibit by 50% the kinase activity of Cdc25A-bound cdk2 compared to the general pool of cyclin-cdk2 (Fig. 5A, lanes 2 and 4). Further, the Cdc25A-bound cdk2 retained 30 to 40% of the residual kinase activity despite the addition of p21 at micromolar concentrations (lanes 5 and 6 and data not shown). Therefore, Cdc25A-bound cdk2 was protected from kinase inhibition by p21.

A trivial explanation of this result could be that the GST-Cdc25A-complexed histone kinase was partly composed of non-cdk2 kinase and was therefore resistant to p21. To rule this out, the cell lysate was precleared with anti-cdk2 antibody before the isolation of GST-Cdc25A on glutathione agarose beads (Fig. 5B). Histone H1 kinase activity recovered with GST-Cdc25A was consistently removed by preclearing with anti-cdk2 antibody, suggesting that all the histone H1 kinase that coprecipitated with GST-Cdc25A was due to cdk2. Histone kinase was not immunoprecipitated from the lysates non-specifically by other nonspecific antibodies (data not shown). Therefore, the p21-resistant histone kinase associated with Cdc25A noted in Fig. 5A (top) is cyclin-cdk2.

As shown by us and many other groups, p21 efficiently as-

sociates with and inhibits cyclin-cdk that has already been activated by Cdc25A and is free of the phosphatase. Therefore, the protection of the cdk2 in the Cdc25A precipitates is also not explained by irreversible activation of the kinase by Cdc25A into a form which is not susceptible to p21. The most likely explanation is that the Cdc25A associated with the cyclin prevents the stable association of p21 with the cyclin-cdk complex, thereby blocking optimal kinase inhibition.

Cdc25A protects DNA replication in *Xenopus* egg extract from inhibition by p21. The above result implies that even in crude biological reactions Cdc25A may protect the cyclin-cdk from inhibition by p21. However Cdc25A2 (with a mutation in the Cy motif) should not be able to protect the kinase from p21. We have demonstrated that p21 inhibits DNA replication in *Xenopus* egg extracts primarily through the inhibition of cyclin-cdk kinase (4), and we exploited this reaction to investigate whether excess Cdc25A diminishes the biological activity of p21 (Fig. 6). Addition of 10 nM p21 inhibited sperm chromatin replication in the interphase extract of *Xenopus* eggs to about 25% of control. A 24-fold excess amount of GST-Cdc25A protected the DNA replication reaction from p21 (Fig. 6A, lane 5 compared to lane 3). GST-Cdc25A did not stimulate replication when added on its own (Fig. 6A, lane 8 compared to lane 1). As predicted, GST-Cdc25A2, which failed to associate with cyclin-cdks, did not protect the replication reaction from p21 (lanes 6 and 7 compared to lanes 2 and 3). Therefore, association of the cyclin with the Cy motif of Cdc25A protects the cyclin-cdks in the *Xenopus* egg extract from inhibition by p21.

DISCUSSION

Cdc25A phosphatase activity dephosphorylates and activates cyclin-cdk complexes during the G_1 -S stage of the cell cycle (18, 19). Cdc25A itself gets phosphorylated and stimulated by cyclin-cdk2 kinases in a positive feedback loop between Cdc25A and cyclin-cdks. Our results confirm previous reports that Cdc25A forms stable complexes with cyclins E, A, D1, and B (Fig. 1A) (11, 18, 19). It is known that the p53-induced cdk




FIG. 5. (A) Cdc25A protects cyclin-cdk2 from inhibition by p21. For each lane in the top panel, cdk2 associated with GST-Cdc25A was isolated from 2.5×10^6 293T cells transfected with EBG-Cdc25A by affinity purification on glutathione agarose beads. For each lane in the bottom panel total cdk2 was isolated from 5×10^6 293T cells by immunoprecipitation with anti-cdk2 antibody. Kinase reactions were carried out with Cdc25A-associated cdk2 (Cdc25A Assoc.) and with the anti-cdk2 immunoprecipitate (α-cdk2 I.P.) using histone H1 and [γ - 32 P]ATP. Lane 1, baseline kinase reaction. The amount of radiolabel incorporated into H1 was 2,400 cpm (top) or 3,000 cpm (bottom). Lanes 2 to 6, indicated concentrations of p21 added to the kinase reactions. (B) The histone kinase associated with GST-Cdc25A is cyclin-cdk2. An extract of 293T cells transfected with pEBG-Cdc25A was immunodepleted by three cycles of immunoprecipitation with anti-cdk2 polyclonal antibody. GST-Cdc25A-associated kinase was isolated by affinity purification on glutathione agarose beads (lanes 1 and 2), or total cdk2 was isolated by immunoprecipitation with anti-cdk2 antibody (lanes 3 and 4) from untreated (lanes 1 and 3) or immunodepleted (lanes 2 and 4) extracts. Kinase reactions were carried out with the precipitates by using histone H1 and [γ - 32 P]ATP as substrates, and an autoradiogram of the phosphorylated histone is shown.




FIG. 6. (A) Cdc25A blocks the inhibition of DNA replication in *Xenopus* egg extract by p21. Replication results in the incorporation of ^{32}P label into nucleic acids that resolves as two bands upon gel electrophoresis (lane 1). GST-p21 (10 nM) was added to the reaction mixtures in lanes 2 to 7. GST, GST-Cdc25A, or GST-Cdc25A2 was added at the indicated concentrations. Cdc25A (lanes 4 and 5) but not Cdc25A2 (lanes 6 and 7) rescued DNA replication in the p21-inhibited reactions. Cdc25A or Cdc25A2 did not stimulate replication when added to reaction mixtures without p21 (lanes 8 and 9). (B) Quantitation of DNA replication by densitometric scanning of an autoradiogram in the linear range of exposure. The densities of both the bands in each lane were added and the background subtracted to quantitate the replication. Replication in lane 1 was taken as 100%.

inhibitor p21^{CIP1} interacts with cyclins by using a conserved Cy motif (3, 5, 25). The consensus motif consists of two basic amino acids followed by two residues with a nonpolar side chain (RRLFG). Cdc25A also contains a similar amino acid sequence on residues 10 to 14 (RRLLF), and our competition experiments with the Cy1-containing peptide PS100 and full-length p21 showed that Cdc25A probably uses a Cy1-like motif to associate with cyclins (Fig. 1B and C). PS100 inhibits the interaction between Cdc25A and cyclin E or A (Fig. 1B) but does not disrupt the association of Cdc25A with cyclin D1, whereas p21 inhibits the interaction of Cdc25A with all three cyclins. These observations are consistent with our earlier results that PS100 did not disrupt the interaction between p21 and cyclin D1 but that a larger peptide containing a similar motif was required to inhibit this association (5). Therefore, the interaction of p21 with cyclin D1 utilizes a larger sequence that includes but is not limited to the Cy1 motif, explaining why p21, but not PS100, inhibited the D1-Cdc25A association.

By site-directed mutagenesis we confirmed that the Cy motif of Cdc25A is used to associate with cyclins *in vitro* as well as *in vivo*. The interaction of Cdc25A with cyclins through the Cy motif of Cdc25A is also important for the removal of a phosphate group from the tyrosine residue of cdk2 in the cyclin-cdk2 complex. Several biologically important substrates and inhibitors of the cyclin-cdk complex use a Cy motif to interact with cyclins. Here we show that an activator of cyclin-cdk2 also uses a similar motif for its interaction with cyclins and for its action on cyclin-cdk2.

Our results show that p21 disrupts the association between cyclin-cdk and Cdc25A. By doing so, p21 blocks the removal of the inhibitory phosphate groups on cdk2 by Cdc25A. So, besides the well-recognized function of inhibiting the cyclin-cdk kinases, p21 also prevents the activation of these kinases by Cdc25A, providing a second mechanism for disrupting the positive feedback loop between Cdc25A and cyclin E-cdk2. This result should not be interpreted to indicate that inhibition of Cdc25A is the sole mechanism by which p21 (and related inhibitors) inhibits cyclin-cdk kinases *in vivo*. Clearly p21 can

effectively inhibit already activated cdk. However, *in vivo*, p21 also has the opportunity to interact with newly synthesized (but inactive) cyclin-cdk, and our results indicate that by doing so p21 has an additional effect, namely, the prevention of activation by Cdc25A. The increased level of phosphotyrosine on p21-complexed cdk2 shown in Fig. 4B confirms that this additional mechanism is operative *in vivo*.

p21 has also been reported to prevent the activation of cdk2 by CAK, which phosphorylates cdk2 on Thr-160 (2). While this is clearly the case *in vitro*, the absence of Thr-160 phosphorylation has not been demonstrated on p21-complexed cdk2 isolated from cells. If Thr-160 phosphorylation were indeed decreased *in vivo* in p21-complexed cdk2, this would be a third mechanism by which p21-complexed cdk2 is kept inactive in the cell.

The antagonism of Cdc25A action implies that whenever p21 is induced in a cell, the amount of phosphotyrosine on the cdk2 molecules should increase. We demonstrated this by transfecting a plasmid expressing p21 into cells (Fig. 4B). Terada et al. (41) reported that radiation of NRK cells (expected to induce p21) increases the phosphotyrosine on cdk4 molecules. Although our results were obtained only with cdk2, it is likely that the interaction of p21 with cyclin D1-cdk4 may similarly inhibit Cdc25A action on cdk4, resulting in the observed accumulation of phosphotyrosine on cdk4 molecules. Such an extension of our results could reconcile the two different mechanisms proposed for the block of the cell cycle at the G₁-S transition following irradiation. Cells with a deletion of p21 are impaired in the G₁-S block following radiation, consistent with radiation inactivating cyclin-cdks through the induction of p21 (6). However, in some circumstances the radiation-induced G₁-S block is overcome by cdk4-F17, a mutant form of the cdk4 enzyme that does not require activation by Cdc25A (41). Therefore, the radiation-induced G₁-S block also involves Cdc25A inhibition because it is bypassed by mutant forms of cdk which do not require Cdc25A. These two apparently different mechanisms can be reconciled if in some circumstances p21 associates with newly synthesized cyclin D-




FIG. 7. Model showing that p21 and Cdc25A utilize similar Cy motifs to compete for the same binding site on cyclin. K is the cdk2 binding motif of p21.

cdk4 and inhibits its dephosphorylation and activation by Cdc25A.

Another report shows that serum-starved cells contain cyclin E-cdk2 in a high-molecular-weight complex containing p27 (38). Upon serum addition p27 has to be removed from the complex to form a smaller cyclin E-cdk2 complex before it can be activated by Cdc25A. Since p27 contains cyclin and cdk binding motifs similar to p21, our results may explain why cyclin E-cdk2 complexed with p27 is resistant to Cdc25A.

We also show that Cdc25A protects the cyclin-cdk2 complex from the inhibitory action of p21 (Fig. 5 and 6). This result is particularly impressive because p21 is a potent inhibitor of cyclin-cdks that associates with the kinase with high affinity using both Cy-cyclin and K-cdk interactions (Fig. 7). In contrast, the association of Cdc25A with cyclin-cdks utilizes only the relatively weaker Cy-cyclin interaction. The interaction of Cdc25A with the cdk subunit is a catalytic interaction which is not particularly stable. However, despite this disadvantage, Cdc25A precomplexed with cyclin-cdk2 successfully blocked inhibition by p21. The prior association of Cdc25A with cyclin-cdk2 may neutralize the disadvantage stemming from its lower affinity for cyclin-cdk2 compared to p21. We demonstrated earlier that reagents like the PS100 peptide or CP36 anti-p21 monoclonal antibody, which interfere with the association of p21 with the cyclin, successfully block the stable association of p21 with the cyclin-cdk complex (5). Perhaps the association of the Cy site of p21 with the cyclin is a docking (low affinity) interaction which is a prerequisite for the subsequent (high affinity) interaction of the K site of p21 with cdk2. Cdc25A precomplexed with the cyclin blocks the docking interaction and thus prevents the stable association with the cdk necessary for optimal kinase inhibition. This is the first example of a cellular molecule which plays such a role vis-a-vis the p21 class of cdk inhibitors.

Therefore there is a competition between p21, a cell cycle inhibitor, and Cdc25A, a cell growth activator, for their target molecule (Fig. 7). The Myc oncoprotein directly stimulates the expression of Cdc25A (12), and so Myc-transformed cells have elevated levels of Cdc25A. Overexpression of Cdc25A could explain why Myc-transformed cells are resistant to p21 (16). Myc-transformed cells are also resistant to growth suppression by transforming growth factor β , and since some of this growth suppression is mediated by the induction of p27 (1), increased levels of Cdc25A could explain part of this resistance.

The recently solved crystal structure of a portion of p27 complexed with cyclin A-cdk2 indicates how the Cy motif as-

sociates with the MRAILV region conserved among all cyclins (33). We report here that an important activator of the cdks uses a Cy motif to interact with cyclin-cdk kinases, in addition to several inhibitors and biologically relevant substrates. Therefore, the MRAILV portion of cyclins is a landing pad for activators, inhibitors, and substrates for cdks: it is a nodal point that integrates signals from multiple pathways, e.g., growth-inhibitory pathways activated by p53 or transforming growth factor β and growth-stimulatory pathways induced by oncogenes like Myc or Cdc25A.

ACKNOWLEDGMENTS

This work was supported by grants to A.D. from the American Cancer Society (VM-161), the Massachusetts Department of Public Health, and the U.S. Armed Forces Medical Research and Materiel Command (DAMD17-94-J-4064). B.J.M. is an Assistant Investigator at the Howard Hughes Medical Institute.

REFERENCES

- Alexandrow, M. G., M. Kawabata, M. Aakre, and H. L. Moses. 1995. Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor. *Proc. Natl. Acad. Sci. USA* **92**:3239-3243.
- Aprelikova, O., Y. Xiong, and E. T. Liu. 1995. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. *J. Biol. Chem.* **270**:18195-18197.
- Chen, I. T., M. Akamatsu, M. L. Smith, F. D. T. Lung, D. Duba, P. P. Roller, A. J. Fornace, and P. M. O'Connor. 1996. Characterization of p21(Cip1/Waf1) peptide domains required for cyclin E/cdk2 and PCNA interaction. *Oncogene* **12**:595-607.
- Chen, J., P. K. Jackson, M. W. Kirschner, and A. Dutta. 1995. Separate domains of p21 involved in the inhibition of cdk kinase and PCNA. *Nature* **374**:386-388.
- Chen, J., P. Saha, S. Kornbluth, B. Dynlacht, and A. Dutta. 1996. Cyclin-binding motifs are essential for the function of p21^{CIP1}. *Mol. Cell. Biol.* **16**:4673-4682.
- Deng, C. X., P. M. Zhang, J. W. Harper, S. J. Elledge, and P. Leder. 1995. Mice lacking p21(cip1/waf1) undergo normal development, but are defective in G1 checkpoint control. *Cell* **82**:675-684.
- Dulic, V., E. Lees, and S. Reed. 1992. Association of human cyclin E with periodic G1-S phase protein kinase. *Science* **257**:1958-1961.
- el Deiry, W. S., J. W. Harper, P. M. O'Connor, V. E. Velculescu, C. E. Canman, J. Jackman, J. A. Pietersen, M. Burrell, D. E. Hill, Y. S. Wang, et al. 1994. Waf1/CIP1 is induced in p53-mediated g(1) arrest and apoptosis. *Cancer Res.* **54**:1169-1174.
- Elledge, S. J. 1996. Cell cycle checkpoints: preventing an identity crisis. *Science* **274**:1664-1672.
- Evans, T., E. T. Rosenthal, J. Youngblom, D. Distel, and T. Hunt. 1983. Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. *Cell* **33**:389-396.
- Galaktionov, K., and D. Beach. 1991. Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. *Cell* **67**:1181-1194.
- Galaktionov, K., X. Chen, and D. Beach. 1996. Cdc25A cell-cycle phosphatase as a target of c-myc. *Nature* **382**:511-517.
- Galaktionov, K., A. Lee, J. Eckstein, G. Draetta, J. Meckler, M. Loda, and D. Beach. 1996. CDC25 phosphatase as potential human oncogene. *Science* **269**:1575-1577.
- Gu, Y., J. Rosenblatt, and D. O. Morgan. 1992. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. *EMBO J.* **11**:3995-4005.
- Hannon, G. J., D. Demetrick, and D. Beach. 1993. Isolation of the Rb-related p130 through its interaction with CDK2 and cyclins. *Genes Dev.* **7**:2378-2391.
- Hermeking, H., J. O. Funk, M. Reichert, J. W. Rllwart, and D. Eick. 1995. Abrogation of p53-induced cell cycle arrest by c-Myc: evidence for an inhibitor of p21-WAF1/CIP1/SDI1. *Oncogene* **11**:1409-1415.
- Hoffmann, I., P. Clarke, M. Marcote, E. Karsenti, and G. Draetta. 1993. Phosphorylation and activation of human cdc25C by cdc2-cyclin B and its involvement in the self-amplification of MPF at mitosis. *EMBO J.* **12**:53-63.
- Hoffmann, I., G. Draetta, and E. Karsenti. 1994. Activation of the phosphatase activity of human cdc25A by a cdc2-cyclin E dependent phosphorylation at the G1-S transition. *EMBO J.* **13**:4302-4310.
- Jinno, S., K. Suto, A. Nagata, et al. 1994. cdc25A is a novel phosphatase functioning early in the cell cycle. *EMBO J.* **13**:1549-1556.
- King, R. W., R. J. Deshaies, J. M. Peters, and M. W. Kirschner. 1996. How

- proteolysis drives the cell cycle. *Science* **274**:1652-1659.
21. **Krek, W., G. Xu, and D. M. Livingstone.** 1995. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. *Cell* **83**:1149-1158.
 22. **Leiter, L. M., J. Chen, T. Marathe, M. Tanaka, and A. Dutta.** 1996. Loss of transactivation and transrepression function, and not RPA binding, alters growth suppression by p53. *Oncogene* **12**:2661-2668.
 23. **Li, R., S. Waga, G. J. Hannon, D. Beach, and B. Stillman.** 1994. Differential effects by the p21 cdk inhibitor on PCNA-dependent DNA replication and repair. *Nature* **371**:534-537.
 24. **Li, Y., C. Graham, S. Lacy, A. M. V. Duncan, and P. Whyte.** 1993. The adenovirus E1A-associated 130 kD protein is encoded by a member of the retinoblastoma gene family and physically interacts with cyclins A and E. *Genes Dev.* **7**:2366-2377.
 25. **Lin, J., C. Reichner, X. Wu, and A. J. Levine.** 1996. Analysis of wild-type and mutant p21^{WAF-1} gene activities. *Mol. Cell. Biol.* **16**:1786-1793.
 26. **Luo, Y., J. Hurwitz, and J. Massague.** 1995. Cell-cycle inhibition by independent cdk and PCNA binding domains in p21-CIP1. *Nature* **375**:159-161.
 27. **Mayer, B. J., H. Hirai, and R. Sakai.** 1995. Evidence that SH2 domains promote processive phosphorylation by protein tyrosine kinase. *Curr. Biol.* **5**:296-305.
 28. **Millar, J. B., C. H. McGowan, G. Lenaers, R. Jones, and P. Russel.** 1991. p80cdc25 mitotic inducer is the tyrosine phosphatase that activates p34cdc2 kinase in fission yeast. *EMBO J.* **10**:4301-4309.
 29. **Morgan, D. O.** 1995. Principles of CDK regulation. *Nature* **374**:131-134.
 30. **Nagata, A., M. Igarashi, S. Jinno, S. K., and H. Okayama.** 1991. An additional homolog of the fission yeast *cdc25+* gene occurs in humans and is highly expressed in some cancer cells. *New Biol.* **3**:959-967.
 31. **Nasmyth, K.** 1996. Viewpoint: putting the cell cycle in order. *Science* **274**:1643-1645.
 32. **Ohtsubo, M., and J. M. Roberts.** 1993. Cyclin-dependent regulation of G1 in mammalian fibroblast. *Science* **259**:1908-1912.
 33. **Russo, A. A., P. D. Jeffry, A. K. Patten, J. Massague, and N. P. Pavletich.** 1996. Crystal structure of the p27(Kip1) cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. *Nature* **382**:325-331.
 34. **Sandhu, K., S. I. Reed, H. Richardson, and P. Russell.** 1990. Human homolog of fission yeast *cdc25* mitotic inducer is predominantly expressed in G2. *Proc. Natl. Acad. Sci. USA* **87**:5139-5143.
 35. **Sherr, J.** 1996. Cancer cell cycle. *Science* **274**:1672-1677.
 36. **Shivji, M. K., S. T. Grey, U. P. Strausfeld, R. D. Wood, and J. J. Blow.** 1994. Cip1 inhibits DNA replication but not PCNA-dependent nucleotide excision-repair. *Curr. Biol.* **4**:1062-1068.
 - 36a. **Silberman, E. D., and B. J. Mayer.** Unpublished data.
 37. **Solomon, M., T. Lee, and M. Kirschner.** 1992. Role of phosphorylation in p34^{cdc2} activation: identification of an activating kinase. *Mol. Biol. Cell.* **3**:13-27.
 38. **Steiner, P., A. Philipp, J. Lukas, D. Godden-Kent, M. Pagano, S. Mittnacht, J. Bartek, and M. Eilers.** 1995. Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. *EMBO J.* **14**:4814-4826.
 39. **Stillman, B.** 1996. Cell cycle control of DNA replication. *Science* **274**:1659-1664.
 40. **Strausfeld, U. P., M. Howell, R. Rempel, J. L. Maller, T. Hunt, and J. J. Blow.** 1994. Cip1 blocks the initiation of DNA replication in *Xenopus* extracts by inhibition of cyclin-dependent kinases. *Curr. Biol.* **4**:876-883.
 41. **Terada, Y., M. Tatsuka, S. Jinno, and H. Okayama.** 1995. Requirement for tyrosine phosphorylation of Cdk4 in G1 arrest induced by ultraviolet irradiation. *Nature* **376**:358-362.
 42. **Waga, S., G. J. Hannon, D. Beach, and B. Stillman.** 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. *Nature* **369**:574-578.
 43. **Zheng, X. F., and J. V. Ruderman.** 1993. Functional analysis of the P box, a domain in cyclin B required for the activation of Cdc25. *Cell* **75**:155-164.
 44. **Zhu, L., E. Harlow, and B. D. Dynlacht.** 1995. p107 uses a p21-related domain to bind cyclin/cdk2 and regulate interactions with E2F. *Genes Dev.* **9**:1740-1752.